St Jude Medical’s first controlled study on deep brain stimulation (DBS) confirms the benefits of a constant current system for patients with Parkinson’s disease (PD).

The Libra and LibraXP systems incorporate a neurostimulator, a surgically implanted battery-operated device that generates mild electrical pulses and carries these pulses to a targeted area in the brain via leads.

The study enrolled 136 patients that, on average, had suffered from PD for at least five years, had moderate to severe dyskinesia, and experienced six or more hours a day of diminished motor symptom control. The aim was to determine the efficacy of Libra and LibraXP DBS constant current systems in managing the symptoms of PD.

In the study, patients receiving stimulation had a 73% response rate compared with a 38% response rate in the group without stimulation, and motor scores for those in the stimulation group improved 39% compared with the baseline as measured by the Unified Parkinson’s Disease Rating Scale (UPDRS).

The primary endpoint of the study was defined as an increase in the duration of ‘on time’ without bothersome dyskinesia when measured after three months. The study demonstrated that participants in the stimulation group averaged an increase of 4.27 hours of ‘on time’, compared with an increase of 1.77 hours in the group without stimulation.

National Parkinson Foundation national medical director Michael Okun said this data epresents a new approach to deep brain stimulation treatment and provides new evidence supporting the positive benefits DBS therapy can provide patients. "These results are important as they represent the first large, randomised, controlled study of a constant current device for managing the symptoms of Parkinson’s disease," Okun said.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

St Jude Medical Neuromodulation Division president Rohan Hoare said the results confirm the benefit of the constant current deep brain stimulation device platform and lay the foundation for future therapy innovation.

Currently, Libra and LibraXP neurostimulators are approved for use in managing the symptoms of PD throughout Europe, Latin America and Australia.